subgroup of
trial)
→
CapableOf
→
match patient
| Typicality: | 0.250 |
| Saliency: | 0.000 |
| to targeted cancer therapies | 3 | transitive-object |
| phase trial → match → patient | 3 |
| negative | neutral | positive |
| 0.014 | 0.910 | 0.075 |
| Raw frequency | 3 |
| Normalized frequency | 0.000 |
| Modifier score | 0.500 |
| Perplexity | 427.394 |